New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

Analysis of Trump’s ‘Most Favoured Nation’ Executive Order on drug pricing, its global impact, price convergence aims, and ...

Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the ...

The UK is confronting a seismic demographic shift with an ageing population and declining fertility rates. In preparing for this change, it is critical that we shift how we think about health across ...

The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets, 2025. These ...

This calculator is built and hosted by OHE, and owned, funded, and commissioned by Pfizer. Before proceeding, please read the following important information regarding its use. This calculator ...

Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs and health-focused policies could help boost productivity, reduce costs, and ...

To help inform the current debate on assisted dying, we have updated the findings of our 2019 palliative report with the latest data. A previous OHE report in 2019 estimated that 378, 427 people in ...

For the growing number of multi-indication medicines, challenges arise in assessing and paying for value across medicine indications with a uniform price (see our previous report and further ...

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...